SEC Form 3 · accession 0001209191-18-052304
Urovant Sciences Ltd. · UROV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pierre Legault
Director
Period of report
Sep 26, 2018
Accepted (ET)
Sep 26, 2018 · 4:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001740547
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | holding | — | — | — | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $7.53 | holding | — | — | — | — | Jun 9, 2028 | Common Shares | 13,350 | — | D |
Explanation of responses
- F1The shares underlying the option shall vest and become exercisable in three equal annual installments beginning on June 10, 2019, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date.
Remarks
Exhibit List - Exhibit 24.1 - Power of Attorney